With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Today, the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) was held. In or…
First patient enrolled in US clinical program
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first patient has been enro…